Protein Scaffolds Proteingerüste Structures Protéiques

Total Page:16

File Type:pdf, Size:1020Kb

Protein Scaffolds Proteingerüste Structures Protéiques (19) TZZ _ _T (11) EP 2 215 246 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C12N 15/10 (2006.01) C12N 15/62 (2006.01) 07.01.2015 Bulletin 2015/02 C07K 14/78 (2006.01) C40B 40/10 (2006.01) (21) Application number: 08845766.8 (86) International application number: PCT/US2008/012398 (22) Date of filing: 31.10.2008 (87) International publication number: WO 2009/058379 (07.05.2009 Gazette 2009/19) (54) PROTEIN SCAFFOLDS PROTEINGERÜSTE STRUCTURES PROTÉIQUES (84) Designated Contracting States: US-B1- 6 482 410 US-B1- 6 818 418 AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT • KOIDE A ET AL: "The fibronectin type III domain RO SE SI SK TR as a scaffold for novel binding proteins", JOURNAL OF MOLECULAR BIOLOGY, LONDON, (30) Priority: 31.10.2007 US 984209 P GB, vol. 284, no. 4, 11 December 1998 (1998-12-11), pages 1141-1151, XP004455886, (43) Date of publication of application: ISSN: 0022-2836, DOI: DOI:10.1006/JMBI. 11.08.2010 Bulletin 2010/32 1998.2238 • BATORI V ET AL: "Exploring the potential of the (73) Proprietor: MedImmune, LLC monobody scaffold:effects of loop elongation on Gaithersburg, MD 20878 (US) the stability of a fibronectin type III domain", PROTEIN ENGINEERING, OXFORD UNIVERSITY (72) Inventors: PRESS, SURREY, GB, vol. 15, no. 12, 1 January • WU, Herren 2002 (2002-01-01), pages 1015-1020, Boyds,MD 20841 (US) XP002996047, ISSN: 0269-2139, DOI: DOI: • BACA, Manuel 10.1093/PROTEIN/15.12.1015 Gaithersburg,MD 20878 (US) • KOIDE AKIKO ET AL: "Monobodies: antibody •SWERS,Jeffrey mimics based on the scaffold of the fibronectin Rockville,MD 20852 (US) type III domain", METHODS IN MOLECULAR • CHACKO, Benoy BIOLOGY, HUMANA PRESS INC, NJ, US, vol. 352, Gaithersburg,MD 20878 (US) 1 January 2007 (2007-01-01), pages 95-109, XP009102789, ISSN: 1064-3745 (74) Representative: Ttofi, Evangelia • KARATAN E ET AL: "Molecular Recognition MedImmune Limited Properties of FN3 Monobodies that Bind the Src Milstein Building SH3 Domain", CHEMISTRY AND BIOLOGY, Granta Park CURRENT BIOLOGY, LONDON, GB, vol. 11, no. Cambridge 6, 1 June 2004 (2004-06-01), pages 835-844, Cambridgeshire CB21 6GH (GB) XP025940205, ISSN: 1074-5521, DOI: DOI: 10.1016/J.CHEMBIOL.2004.04.009 [retrieved on (56) References cited: 2004-06-25] WO-A2-2005/056764 US-A- 6 160 089 US-A1- 2006 073 559 US-A1- 2007 098 681 Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention). EP 2 215 246 B1 Printed by Jouve, 75001 PARIS (FR) (Cont. next page) EP 2 215 246 B1 • GILL D S ET AL: "Biopharmaceutical drug discovery using novel protein scaffolds", CURRENT OPINION IN BIOTECHNOLOGY, LONDON, GB, vol. 17, no. 6, 1 December 2006 (2006-12-01), pages653-658, XP024962817, ISSN: 0958-1669, DOI: DOI:10.1016/J.COPBIO. 2006.10.003 [retrieved on 2006-12-01] 2 EP 2 215 246 B1 Description 1. FIELD OF THE INVENTION 5 [0001] This invention relates to protein scaffolds that specifically bind a target and methods of making, screening and using such scaffolds. 2. BACKGROUND OF THE INVENTION 10 [0002] This invention relates to protein scaffolds useful, for example, for the generation of products having novel binding characteristics. [0003] Proteins having relatively defined three-dimensional structures, commonly referred to as protein scaffolds, may be used as reagents for the design of engineered products. These scaffolds typically contain one or more regions which are amenable to specific or random sequence variation, and such sequence randomization is often carried out to produce 15 libraries of proteins from which desired products may be selected. One particular area in which such scaffolds are useful is the field of antibody mimetic design. [0004] While therapeutic antibodies are known with some successful examples on the market (HERCEPTIN®, AVAS- TIN®, SYNAGIS®), there is a growing interest in generating antibody fragments as therapeutic proteins. The advantages are the ease of manipulation by molecular biology techniques in order to obtain desired binding characteristics, the ability 20 to express such fragments in microbial systems, and the expectation that antibody fragments will have better tissue penetration than full-length antibodies. One example is REOPRO®. [0005] In addition, there have been efforts to develop small, non-antibody therapeutics,i.e., antibody mimetics, in order to capitalize on the advantages of antibodies and antibody fragments, such as high affinity binding of targets and low immunogenicity and toxicity, while avoiding some of the shortfalls, such as the requirement for intradomain disulfide 25 bonds which require proper refolding, and the tendency for antibody fragments to aggregate and be less stable than full-length IgGs. One example is a "minibody" scaffold, which is related to the immunoglobulin fold, which is designed by deleting three beta strands from a heavy chain variable domain of a monoclonal antibody (Tramontano et al., J. Mol. Recognit. 7:9, 1994). This protein includes 61 residues and can be used to present two hypervariable loops, much like complementarity determining regions (CDRs) in antibodies. These two loops have been randomized and products 30 selected for antigen binding, but thus far the framework appears to have somewhat limited utility due to solubility problems. Another framework used to display loops has been tendamistat, a small protein inhibitor of α-amylase, which contains a 74 residue, six-strand beta sheet sandwich held together by two disulfide bonds and forms 3 CDR-like loops (McConnell and Hoess, J. Mol. Biol. 250:460, 1995). [0006] Other proteins have been tested as frameworks and have been used to display randomized residues on alpha 35 helical surfaces (Nord et al., Nat. Biotechnol. 15:772, 1997; Nord et al., Protein Eng. 8:601, 1995), loops between alpha helices in alpha helix bundles (Ku and Schultz, Proc. Natl. Acad. Sci. USA 92:6552, 1995), and loops constrained by disulfide bridges, such as those of the small protease inhibitors (Markland et al., Biochemistry 35:8045, 1996; Markland et al., Biochemistry 35:8058, 1996; Rottgen and Collins, Gene 164:243, 1995; Wang et al., J. Biol. Chem. 270:12250, 1995). 40 [0007] Koide A et al.: "The fibronectin type III domain as a scaffold for novel binding proteins", Journal Of Molecular Biology, vol. 284, no. 4, 11 December 1998 (1998-12-11), pages 1141-1151 describe preparation of a phage display library of FN3 in which residues in two surface loops were randomized. Mutant FN3s were selected that bound a test ligand, ubiquitin, with significant affinities; the wild-type FN3 showed no measurable affinity. [0008] Batori V et al.: "Exploring the potential of the monobody scaffold: effects of loop elongation on the stability of 45 a fibronectin type III domain", Protein Engineering, vol. 15, no. 12, 1 January 2002, pages 1015-1020, describe devel- opment of small antibody mimics, ’monobodies’, using the tenth fibronectin type III domain of human fibronectin (FNfn10) as a scaffold. Initially, alterations were made in two loops of FNfn10 that were structurally equivalent to two of the hypervariable loops of the immunoglobulin domain. To assess the possibility of utilizing other loops in FNfn10 for target binding, the effects of the elongation of each loop on the conformational stability of FNfn10 was investigated. The results 50 suggested that all loops, except for the EF loop, could be used for engineering a binding site. [0009] Koide Akiko et al.: "Monobodies: antibody mimics based on the scaffold of the fibronectin type III domain", Methods in Molecular Biology, vol. 352, 1 January 2007, pages 95-109, described the use of the 10th fibronectin type III domain of human fibronectin (FNfn10) as a scaffold to display multiple surface loops for target binding. [0010] Karatan E et al.: "Molecular Recognition Properties of FN3 Monobodies that Bind the Src SH3 Domain", Chem- 55 istry and Biology, Current Biology, vol. 11, no. 6, 1 June 2004, pages 835-844, described construction of a phage- displayed library based on the human fibronectin tenth type III domain (FN3) scaffold by randomizing residues in its FG and BC loops. Competitive binding, loop replacement, and NMR perturbation experiments were conducted to analyse the recognition properties of selected binders. 3 EP 2 215 246 B1 [0011] WO 2005/056764 A2 describes single domain polypeptides that bind to vascular endothelial growth factor receptor 2 (VEGFR-2). [0012] Gill D S et al.: "Biopharmaceutical drug discovery using novel protein scaffolds", Current Opinion In Biotech- nology, vol. 17, no. 6, 1 December 2006, pages 653-658, reviewed the development of novel protein scaffold technologies, 5 including single-domain antibodies, small modular immunopharmaceuticals, tetranectins, AdNectins, A-domain proteins, lipocalins and ankyrin repeat proteins. [0013] US 6 818 418 B1 (Lipovsek et al.) discloses proteins that include a fibronectin type III domain having at least one randomized loop. [0014] Thus, there is a need to develop small, stable, artificial antibody-like molecules for a variety of therapeutic and 10 diagnostic applications. [0015] Citation or discussion of a reference herein shall not be construed as an admission that such is prior art to the present invention. 3. SUMMARY OF THE INVENTION 15 [0016] The present invention provides a recombinant polypeptide scaffold comprising: I. seven beta strand domains designated A, B, C, D, E, F, and G; II.
Recommended publications
  • EURL ECVAM Recommendation on Non-Animal-Derived Antibodies
    EURL ECVAM Recommendation on Non-Animal-Derived Antibodies EUR 30185 EN Joint Research Centre This publication is a Science for Policy report by the Joint Research Centre (JRC), the European Commission’s science and knowledge service. It aims to provide evidence-based scientific support to the European policymaking process. The scientific output expressed does not imply a policy position of the European Commission. Neither the European Commission nor any person acting on behalf of the Commission is responsible for the use that might be made of this publication. For information on the methodology and quality underlying the data used in this publication for which the source is neither Eurostat nor other Commission services, users should contact the referenced source. EURL ECVAM Recommendations The aim of a EURL ECVAM Recommendation is to provide the views of the EU Reference Laboratory for alternatives to animal testing (EURL ECVAM) on the scientific validity of alternative test methods, to advise on possible applications and implications, and to suggest follow-up activities to promote alternative methods and address knowledge gaps. During the development of its Recommendation, EURL ECVAM typically mandates the EURL ECVAM Scientific Advisory Committee (ESAC) to carry out an independent scientific peer review which is communicated as an ESAC Opinion and Working Group report. In addition, EURL ECVAM consults with other Commission services, EURL ECVAM’s advisory body for Preliminary Assessment of Regulatory Relevance (PARERE), the EURL ECVAM Stakeholder Forum (ESTAF) and with partner organisations of the International Collaboration on Alternative Test Methods (ICATM). Contact information European Commission, Joint Research Centre (JRC), Chemical Safety and Alternative Methods Unit (F3) Address: via E.
    [Show full text]
  • WO 2017/013231 Al 26 January 2017 (26.01.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2017/013231 Al 26 January 2017 (26.01.2017) P O P C T (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, C07K 14/705 (2006.01) C07K 16/00 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/EP20 16/067468 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 2 1 July 20 16 (21 .07.2016) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/194,882 2 1 July 2015 (21.07.2015) TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 62/364,414 20 July 2016 (20.07.2016) TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (72) Inventors; and LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, (71) Applicants : XIANG, Sue D.
    [Show full text]
  • Understanding Ubiquitin Recognition and Generating Affinity Reagents
    Ubiquitin Engineering: Understanding Ubiquitin Recognition and Generating Affinity Reagents by Isabel Leung A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Department of Molecular Genetics University of Toronto © Copyright by Isabel Leung 2017 Abstract Ubiquitin Engineering: Understanding Ubiquitin Recognition and Generating Affinity Reagents Isabel Leung Doctor of Philosophy Department of Molecular Genetics University of Toronto 2016 Protein-protein interactions are necessary for virtually all biological processes. There have been tremendous efforts to document the diversity of molecular recognition, and to understand how molecular recognition occurs. The understanding of molecular interaction has also served as the foundation for designing novel protein interactions for use in therapeutics, diagnostics and basic sciences. An attractive system for studying protein-protein interactions is the ubiquitin (Ub) system. Ub is a protein modifier that is combinatorially ligated onto substrate proteins to influence substrate turnover and function. Ub uses a common surface to interact with more than 1000 proteins and plays pivotal roles in cell physiology. Despite the substantial structural information on Ub mediated interactions, there is no clear understanding of how individual Ub residues contribute to Ub’s broad scope of interactions. To address this question, I used affinity enhanced Ub variants (Ubvs) as proxies of native Ub in saturation scanning. Using saturation scanning, I studied the interactions between Ubvs and two Ub specific proteases (USP), USP2 and USP21, and elucidated a common functional epitope that is critical for USP recognition. The functional epitope recognizes USP residues that are conserved among the human USP family, suggesting it may make functional contributions in many other USP interactions.
    [Show full text]
  • University of Copenhagen, DK-2200 København N, Denmark * Correspondence: [email protected]; Tel.: +45-2988-1134 † These Authors Contributed Equally to This Work
    Toxin Neutralization Using Alternative Binding Proteins Jenkins, Timothy Patrick; Fryer, Thomas; Dehli, Rasmus Ibsen; Jürgensen, Jonas Arnold; Fuglsang-Madsen, Albert; Føns, Sofie; Laustsen, Andreas Hougaard Published in: Toxins DOI: 10.3390/toxins11010053 Publication date: 2019 Document version Publisher's PDF, also known as Version of record Citation for published version (APA): Jenkins, T. P., Fryer, T., Dehli, R. I., Jürgensen, J. A., Fuglsang-Madsen, A., Føns, S., & Laustsen, A. H. (2019). Toxin Neutralization Using Alternative Binding Proteins. Toxins, 11(1). https://doi.org/10.3390/toxins11010053 Download date: 09. apr.. 2020 toxins Review Toxin Neutralization Using Alternative Binding Proteins Timothy Patrick Jenkins 1,† , Thomas Fryer 2,† , Rasmus Ibsen Dehli 3, Jonas Arnold Jürgensen 3, Albert Fuglsang-Madsen 3,4, Sofie Føns 3 and Andreas Hougaard Laustsen 3,* 1 Department of Veterinary Medicine, University of Cambridge, Cambridge CB3 0ES, UK; [email protected] 2 Department of Biochemistry, University of Cambridge, Cambridge CB3 0ES, UK; [email protected] 3 Department of Biotechnology and Biomedicine, Technical University of Denmark, DK-2800 Kongens Lyngby, Denmark; [email protected] (R.I.D.); [email protected] (J.A.J.); [email protected] (A.F.-M.); sofi[email protected] (S.F.) 4 Department of Biology, University of Copenhagen, DK-2200 København N, Denmark * Correspondence: [email protected]; Tel.: +45-2988-1134 † These authors contributed equally to this work. Received: 15 December 2018; Accepted: 12 January 2019; Published: 17 January 2019 Abstract: Animal toxins present a major threat to human health worldwide, predominantly through snakebite envenomings, which are responsible for over 100,000 deaths each year.
    [Show full text]
  • Single-Round, Multiplexed Antibody Mimetic Design Through Mrna Display** C
    Angewandte Chemie DOI: 10.1002/anie.201207005 Ligand Design Single-Round, Multiplexed Antibody Mimetic Design through mRNA Display** C. Anders Olson, Jeff Nie, Jonathan Diep, Ibrahim Al-Shyoukh, Terry T. Takahashi, Laith Q. Al- Mawsawi, Jennifer M. Bolin, Angela L. Elwell, Scott Swanson, Ron Stewart, James A. Thomson, H. Tom Soh, Richard W. Roberts, and Ren Sun* There is a pressing need for new technologies to generate fold enrichment. Our results also demonstrate that highly robust, renewable recognition tools against the entire human functional binders (K 100 nm or better) are present with D proteome.[1] Hybridoma-based monoclonal antibodies,[2] the a frequency of > 1 in 109 in our library. standard for protein reagents, are undesirable for this task To begin, we needed to devise an appropriate selection because of the number of animals, amount of target, time, and protocol and library creation format. Typically, in vitro effort required to generate each reagent. Here, we developed selections require multiple rounds of modest sequential a unified approach to solve this problem by integrating four enrichment, followed by small-scale sequencing of functional distinct technologies: 1) a combinatorial protein library based clones (Figure 1A). Indeed, the need to generate a target- on the 10th fibronectin type III domain of human fibronectin specific library at each round provides a significant limitation (10Fn3),[3] 2) protein library display by mRNA display,[4] towards parallelizing and accelerating selections. In contrast, 3) selection by continuous-flow magnetic separation for identification of ligands after a single round of CFMS (CFMS),[5] and 4) sequence analysis by high throughput mRNA display (Figure 1A,B), only a single naive library pool sequencing (HTS).[6] Next generation sequencing has revolu- must be synthesized for any number of targets, drastically tionized many fields of biology, and is increasingly being used decreasing the effort needed for ligand discovery.
    [Show full text]
  • WO 2017/147538 Al 31 August 2017 (31.08.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/147538 Al 31 August 2017 (31.08.2017) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12N 15/85 (2006.01) C12N 15/90 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, PCT/US2017/01953 1 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, 24 February 2017 (24.02.2017) KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (25) Filing Language: English NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (26) Publication Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (30) Priority Data: ZA, ZM, ZW. 62/300,387 26 February 2016 (26.02.2016) U S (84) Designated States (unless otherwise indicated, for every (71) Applicant: POSEIDA THERAPEUTICS, INC. kind of regional protection available): ARIPO (BW, GH, [US/US]; 4242 Campus Point Ct #700, San Diego, Califor GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, nia 92121 (US).
    [Show full text]
  • Expanding the Boundaries of Biotherapeutics with Bispecific
    BioDrugs https://doi.org/10.1007/s40259-018-0299-9 REVIEW ARTICLE Expanding the Boundaries of Biotherapeutics with Bispecifc Antibodies Bushra Husain1 · Diego Ellerman1 © The Author(s) 2018 Abstract Bispecifc antibodies have moved from being an academic curiosity with therapeutic promise to reality, with two molecules being currently commercialized (Hemlibra­ ® and Blincyto­ ®) and many more in clinical trials. The success of bispecifc antibodies is mainly due to the continuously growing number of mechanisms of actions (MOA) they enable that are not accessible to monoclonal antibodies. One of the earliest MOA of bispecifc antibodies and currently the one with the largest number of clinical trials is the redirecting of the cytotoxic activity of T-cells for oncology applications, now extending its use in infective diseases. The use of bispecifc antibodies for crossing the blood–brain barrier is another important application because of its potential to advance the therapeutic options for neurological diseases. Another noteworthy application due to its growing trend is enabling a more tissue-specifc delivery or activity of antibodies. The diferent molecular solutions to the initial hurdles that limited the development of bispecifc antibodies have led to the current diverse set of bispecifc or multispecifc antibody formats that can be grouped into three main categories: IgG-like formats, antibody fragment-based formats, or appended IgG formats. The expanded applications of bispecifc antibodies come at the price of additional chal- lenges for clinical development. The rising complexity in their structure may increase the risk of immunogenicity and the multiple antigen specifcity complicates the selection of relevant species for safety assessment.
    [Show full text]
  • WO 2018/035503 Al 22 February 2018 (22.02.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/035503 Al 22 February 2018 (22.02.2018) W !P O PCT (51) International Patent Classification: (71) Applicant: THE REGENTS OF THE UNIVERSITY OF C12N 9/22 (2006.01) C12N 9/16 (2006.01) CALIFORNIA [US/US]; 1111 Franklin Street, 5th Floor, CI2N 15/85 (2006.01) C12N 15/82 (2006.01) Oakland, California 94607-5200 (US). CI2N 15/86 (2006.01) C12N 15/11 (2006.01) (72) Inventors; and C12N 15/861 (2006.01) C12N 15/113 (2010.01) (71) Applicants: MALI, Prashant [US/US]; c/o U C San Diego, CI2N 15/87 (2006.01) A61K 35/76 (2015.01) 9500 Oilman Drive, Mail Code: 0910, La Jolla, California C12N 15/63 (2006.01) 92093 (US). KATREKAR, Dhruva [US/US]; c/o U C San (21) International Application Number: Diego, 9500 Oilman Drive, Mail Code: 0910, La Jolla, Cal¬ PCT/US20 17/047687 ifornia 92093 (US). COLLADO, Ana Moreno [US/US]; c/o U C San Diego, 9500 Oilman Drive, Mail Code: 0910, (22) International Filing Date: La Jolla, California 92093 (US). 18 August 2017 (18.08.2017) (74) Agent: KONSKI, Antoinette F. et al; FOLEY & LARD- (25) Filing Language: English NER LLP, 3000 K Street, N.W., Suite 600, Washington, (26) Publication Language: English District of Columbia 20007-5 109 (US). (30) Priority Data: (81) Designated States (unless otherwise indicated, for every 62/376,855 18 August 2016 (18.08.2016) U S kind of national protection available): AE, AG, AL, AM, 62/415,858 0 1 November 20 16 (01 .11.20 16) U S AO, AT, AU, AZ, BA, BB, BO, BH, BN, BR, BW, BY, BZ, 62/481,589 04 April 20 17 (04 .04 .20 17) U S CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (54) Title: CRISPR-CAS GENOME ENGINEERING VIA A MODULAR AAV DELIVERY SYSTEM sgR A o Fig.
    [Show full text]
  • Thesis + Long Intro
    Engineered discoidin domain from factor VIII binds αvβ3 integrin with antibody-like affinity Thesis by Gene Kym In Partial Fulfillment of the Requirements for the degree of Doctor of Philosophy CALIFORNIA INSTITUTE OF TECHNOLOGY Pasadena, California 2014 (Defended April 23rd, 2014) ii © 2014 Gene Kym All Rights Reserved iii ACKNOWLEDGEMENTS I would like to thank my family for encouraging my studies and keeping me focused on long-term goals. I am thankful for the teachers who educated me, the mentors who trained me, my colleagues in student organizations who showed me the power of teamwork, and my friends for teaching me about the world outside the of academia. I am grateful to Steve, the Mayo Lab, and the individuals at Caltech who made my doctoral years a time of exploration, learning, and fun. iv ABSTRACT Alternative scaffolds are non-antibody proteins that can be engineered to bind new targets. They have found useful niches in the therapeutic space due to their smaller size and the ease with which they can be engineered to be bispecific. We sought a new scaffold that could be used for therapeutic ends and chose the C2 discoidin domain of factor VIII, which is well studied and of human origin. Using yeast surface display, we engineered the C2 domain to bind to αvβ3 integrin with a 16 nM affinity while retaining its thermal stability and monomeric nature. We obtained a crystal structure of the engineered domain at 2.1 Å resolution. We have christened this discoidin domain alternative scaffold the “discobody.” v TABLE OF CONTENTS Acknowledgements .......................................................................................................
    [Show full text]
  • Type of the Paper (Article, Review, Communication
    Review Volume 11, Issue 3, 2021, 10679 - 10689 https://doi.org/10.33263/BRIAC113.1067910689 Selective Preference of Antibody Mimetics over Antibody, as Binding Molecules, for Diagnostic and Therapeutic Applications in Cancer Therapy Pankaj Garg 1,* 1 Department of Chemistry, GLA University, Mathura, 281406, India * Correspondence: [email protected]; Scopus Author ID 571962558738 Received: 5.10.2020; Revised: 3.11.2020; Accepted: 4.11.2020; Published: 7.11.2020 Abstract: Despite wider use of monoclonal and polyclonal antibodies as therapeutic and diagnostic detection agents for different types of cancers, their limitations for biomedical applications have forced scientists to design alternate next-generation molecular binding reagents, the so-called antibody mimetics. The ultimate aim to produce antibody mimetics is to out-perform the intrinsic limitations of antibodies related to their binding affinities, tumor penetration, temperature, and pH stability. The current review highlights the advanced characteristics and constructional modification of alternate antibody mimetics, compared to animal source generated antibodies and their improved applications in bioanalytical chemistry; especially in cancer treatment as a diagnostic and therapeutic tool. Keywords:Antibody mimetic; Monoclonal antibodies (MoAbs); Protein scaffold engineering; Molecular Imaging; cancer therapy. © 2020 by the authors. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). 1. Introduction Antibodies, especially monoclonal antibodies, on account of their high stability and specific affinity, have been identified as effective tools both for therapeutic and diagnostic applications, especially in cancer therapy. Antibodies are Y-shaped glycoproteins produced by the immune system to counteract the effect of any foreign substance or antigen in the body.
    [Show full text]
  • Camelid Single-Domain Antibody Directed Against Amyloid Bêta and Methods for Producing Conjugates Thereof
    (19) TZZ ¥_T (11) EP 2 873 679 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 20.05.2015 Bulletin 2015/21 C07K 16/18 (2006.01) A61K 49/16 (2006.01) A61K 51/10 (2006.01) (21) Application number: 13306553.2 (22) Date of filing: 13.11.2013 (84) Designated Contracting States: • Delatour, Benoît AL AT BE BG CH CY CZ DE DK EE ES FI FR GB 94230 Cachan (FR) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • Dhenain, Marc PL PT RO RS SE SI SK SM TR 91470 Limours (FR) Designated Extension States: • Duyckaerts, Charles BA ME 94160 Saint-Mandé (FR) • Li, Tengfei (83) Declaration under Rule 32(1) EPC (expert 92400 Courbevoie (FR) solution) • Vandesquille, Matthias 92260 Fontenay-aux-Roses (FR) (71) Applicants: • Czech, Christian • F.Hoffmann-La Roche AG 79639 Grenzach-Wyhlen (DE) 4070 Basel (CH) • Grueninger, Fiona • INSTITUT PASTEUR 4144 Arlesheim (CH) 75015 Paris (FR) (74) Representative: Rançon, Xavier Lucien Abel et al (72) Inventors: Cabinet Orès • Lafaye, Pierre 36, rue de Saint Pétersbourg 92240 Malakoff (FR) 75008 Paris (FR) • Bay, Sylvie 75012 Paris (FR) (54) Camelid single-domain antibody directed against amyloid bêta and methods for producing conjugates thereof (57) The present invention relates to variable domain of a camelid heavy- chain antibodies directed to amyloid β and conjugates thereof. The present invention also relates to the use of these antibody conjugates for treating or diagnosing disorders mediated by amyloid β deposits. EP 2 873 679 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 873 679 A1 Description [0001] The present invention relates to antibodies directed to amyloid β and conjugates thereof.
    [Show full text]
  • An Albumin-Binding Domain As a Scaffold for Bispecific Affinity Proteins
    An albumin-binding domain as a scaffold for bispecific affinity proteins J o h a n n i lv e B r a n T Doctoral Thesis in Biotechnology Stockholm, Sweden 2012 An albumin-binding domain as a scaffold An albumin-binding domain as a scaffold for bispecific affinity proteins for bispecific affinity proteins JOHAN NILVEBRANT JOHAN NILVEBRANT Royal Institute of Technology Royal Institute of Technology School of Biotechnology School of Biotechnology Stockholm 2012 Stockholm 2012 © Johan Nilvebrant © Johan Nilvebrant Stockholm 2012 Stockholm 2012 Royal Institute of Technology Royal Institute of Technology School of Biotechnology School of Biotechnology AlbaNova University Center AlbaNova University Center SE-106 91 Stockholm SE-106 91 Stockholm Sweden Sweden Printed by E-Print Printed by E-Print Oxtorgsgatan 9 Oxtorgsgatan 9 SE-111 57 Stockholm SE-111 57 Stockholm Sweden Sweden ISBN 978-91-7501-569-9 ISBN 978-91-7501-569-9 TRITA-BIO Report 2012:21 TRITA-BIO Report 2012:21 ISSN 1654-2312 ISSN 1654-2312 iii iii Johan Nilvebrant (2012): An albumin-binding domain as a scaffold for bispecific affinity Johan Nilvebrant (2012): An albumin-binding domain as a scaffold for bispecific affinity proteins. proteins. Division of Proteomics, School of Biotechnology, Royal Institute of Technology (KTH), Stockholm, Division of Proteomics, School of Biotechnology, Royal Institute of Technology (KTH), Stockholm, Sweden. Sweden. Abstract Abstract Protein engineering and in vitro selection systems are powerful methods to generate binding proteins. Protein engineering and in vitro selection systems are powerful methods to generate binding proteins. In nature, antibodies are the primary affinity proteins and their usefulness has led to a widespread use In nature, antibodies are the primary affinity proteins and their usefulness has led to a widespread use both in basic and applied research.
    [Show full text]